SHH and neoplasm: Regarding medulloblastomas, 28 out of 29 (96.6%) tumours agreed with the initial diagnosis and were subclassified into Group 3 and Group 4 (7 tumours each, 25.0%), followed by SHH‐activated (8 tumours, 28.6%) and WNT‐activated (6 tumours, 21.4%).